Year8
Special Luokai, an Indian cancer drug. Especially for lung cancer patients, it can effectively extend the patient's life. It is an oral targeted therapy drug.
Tarceva, whose English name is r, exists in the form of erlotinib hydrochloride. Tarceva is a round, biconvex, white-coated tablet with brown && and && printed on one side and blank on the other side. So, what is the mechanism of Tarceva?
Tarceva’s mode of action is different from that of chemotherapy. It is a targeted therapy drug that can specifically target tumor cells and inhibit the formation and growth of tumors. . It is a small molecule compound that can inhibit the signaling pathway of human epidermal growth factor receptor (R). It is a key component of the epidermal growth factor (also known as R) signaling pathway and plays an important role in the formation and growth of various tumor cells. played an important role in both. Tarceva inhibits tumor growth by inhibiting the activity of tyrosine kinase, which is one of the important components in R cells.
Tarceva is a highly efficient, highly specific and reversible inhibitor of epidermal growth factor receptor tyrosine kinase. It is a new therapeutic drug that can be used for patients with progressive and metastatic disease after chemotherapy failure. It is an oral tablet that only needs to be taken once a day. It is well tolerated and has good effects on a variety of solid tumors, especially advanced non-small cell lung cancer. -z %>
Tarceva had cardiac dysfunction prior to treatment Patients need to take special care. Approximately/all patients with hypocardia were treated for symptoms, and most of the symptoms improved after treatment. Treatment usually includes diuretics, cardiac glycosides, and/or angiotensin-converting enzyme inhibitors.
Patients selected for treatment with this drug should undergo a comprehensive basic cardiac evaluation, including medical history, physical examination, and one or more of the following tests: echocardiogram, scan.
There are currently no data demonstrating appropriate assessment methods to identify patients at risk for cardiotoxicity. During treatment with this drug, left ventricular function should be evaluated frequently. Discontinuation of Tarceva should be considered in patients who develop clinically significant left ventricular dysfunction.
The vast majority of patients with cardiac symptoms and manifestations who were clinically effective on this drug continued to use Tarceva weekly without developing further clinical cardiac conditions.
In sterile water for injection, phenylethyl alcohol is used as a preservative and is toxic to newborns and children under 10 years of age. When this drug is used in patients with known hypersensitivity to phenylethyl alcohol, it should be reconstituted with water for injection.
Reproductive studies on the use of the drug in pregnant and lactating women were conducted in monkeys. When the dose was given to twice the human weekly maintenance dose (/), no obvious fertility defects or harm to the fetus were found. Transplacental transfer of trastuzumab into the fetus has been observed both early (gestation day) and late (gestation day) during development. It is unclear whether Tarceva will cause fetal damage and affect reproductive capacity when used in pregnant women. Because the results of animal reproduction studies are not predictive of human responses, Tarceva should not be used in pregnant women unless the potential benefit to the mother outweighs the potential risk to the fetus. Tarceva (erlotinib) can be tried as a third-line treatment for locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens. This indication is based on the results of the aforementioned phase III clinical study abroad. The efficacy of second-line treatment for Chinese non-small cell lung cancer needs to be confirmed by further clinical studies. Two multicenter, placebo-controlled, randomized phase III trials in the first-line treatment of patients with locally advanced or metastatic disease showed that there was no clinical benefit in taking erlotinib concurrently with platinum-based chemotherapy (carboplatin + paclitaxel or gemcitabine + cisplatin). benefit and is therefore not recommended as first-line treatment for the above conditions.
Clinically explore the clinical efficacy of Tarceva in the treatment of advanced non-small cell lung cancer. The selected cases were all pathologically confirmed patients with advanced non-small cell lung cancer (NSCLC) who had received at least one regimen of systemic chemotherapy. All patients met the six inclusion criteria and were given Tarceva/Tarceva alone until their disease progressed or they became incapacitated. Tolerable adverse reactions, observe the clinical efficacy and adverse reactions of Tarceva.
Mechanism of Action The clinical anti-tumor action mechanism of erlotinib has not yet been fully clarified. Erlotinib inhibits the phosphorylation of intracellular tyrosine kinases associated with epidermal growth factor receptor (R). Whether it has specific inhibitory effects on other tyrosine kinase receptors has not yet been fully clarified. R is expressed on the surface of normal cells and tumor cells.
The results showed that all patients could be evaluated for efficacy, and the median treatment time was (.&.) months (.~.months). The objective effective rate was .% and the disease control rate was .%. There was no statistical difference in the effects of gender, smoking history, score, pathological type, and clinical stage on the efficacy. When the tumor progresses (&), the median survival time (&), and the annual survival rate are .%. Among them, lung adenocarcinoma has the highest objective effective rate, accounting for .%. The most common adverse reaction was rash, with an incidence rate of .%. It can be concluded that Tarceva has definite efficacy in the treatment of advanced non-small cell lung cancer, has mild adverse reactions and is well tolerated.
WhatsApp
